The results of the meta-analysis showed that the effect size (95% CI = 0.65 [0.23, 0.98], z = 3.76, p < 0.05) was statistically significant, suggesting that the objective response rate of CAR-T cells combined with PD-1 therapy in tumor patients was 65% (Fig. 2C). This evidence concerns the gene PDCD1 and neoplasm.